A Phase I Multicenter, Open-label Study of the Effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-agent Palifosfamide-tris in Subjects With Advanced Solid Tumors.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 10 Oct 2013
At a glance
- Drugs Palifosfamide (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacodynamics
- 17 Jul 2013 Planned end date changed from 1 Aug 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 20 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 29 Jun 2011 Actual initiation date (Jun 2011) added as reported by ClinicalTrials.gov.